Sam Leno Biography and Net Worth

Director of Lantheus

Samuel Leno is a Director, the Chairman of the Audit Committee, and a member of the Nominating and Corporate Governance Committee, serving on the Board of Directors since May 2012. Mr. Leno is a strategic executive with more than 40 years of experience with complex multinational companies. He most recently held the positions of Executive Vice President and Chief Operations Officer at Boston Scientific. He previously served as Executive Vice President, Finance and Information Systems and Chief Financial Officer. He retired from Boston Scientific in December 2011. Prior to joining Boston Scientific, Mr. Leno served as Executive Vice President, Finance and Corporate Services and Chief Financial Officer at Zimmer Holdings, Inc. and Chief Financial Officer positions at Arrow Electronics, Inc., Corporate Express, Inc. and Coram Healthcare. Previously, he held a variety of senior financial positions at Baxter International, Inc. and American Hospital Supply Corporation. He is the Chairman of the Board of Directors and of the Audit Committee of Zest Anchors, Inc. He previously served on the Boards of Directors and the Audit Committees of Omnicare and TomoTherapy, Inc. and also served on the Board of Directors of Endotronix, Inc. Mr. Leno served as a Lieutenant in the United States Navy and is a Vietnam veteran. He holds a Bachelor of Science in Accounting from Northern Illinois University and a Master of Business Administration from Roosevelt University.

What is Sam R. Leno's net worth?: The estimated net worth of Sam R. Leno is at least $2.61 million as of April 8th, 2021. Mr. Leno owns 40,784 shares of Lantheus stock worth more than $2,614,254 as of April 25th. This net worth estimate does not reflect any other investments that Mr. Leno may own. Learn More about Sam R. Leno's net worth.
How do I contact Sam R. Leno?: The corporate mailing address for Mr. Leno and other Lantheus executives is 331 TREBLE COVE ROAD, NORTH BILLERICA MA, 01862. Lantheus can also be reached via phone at (978) 671-8001 and via email at [email protected]. Learn More on Sam R. Leno's contact information.
Has Sam R. Leno been buying or selling shares of Lantheus?: Sam R. Leno has not been actively trading shares of Lantheus within the last three months. Most recently, Sam R. Leno sold 5,000 shares of the business's stock in a transaction on Thursday, April 8th. The shares were sold at an average price of $21.17, for a transaction totalling $105,850.00. Following the completion of the sale, the director now directly owns 40,784 shares of the company's stock, valued at $863,397.28. Learn More on Sam R. Leno's trading history.
Who are Lantheus' active insiders?: Lantheus' insider roster includes Minnie Baylor-Henry (Director), Gerard Ber (Director), Paul Blanchfield (Insider), John Bolla (COO), Michael Duffy (SVP), Mary Heino (CEO), Sam Leno (Director), Heinz Maeusli (Director), Brian Markison (Director), Robert Marshall, Jr. (CFO), Etienne Montagut (Insider), Daniel Niedzwiecki (Insider), Andrea Sabens (CAO), and Carol Walker (SVP). Learn More on Lantheus' active insiders.
Are insiders buying or selling shares of Lantheus?: During the last year, Lantheus insiders bought shares 1 times. They purchased a total of 60,431,039 shares worth more than $57,409,487.05. During the last year, insiders at the medical equipment provider sold shares 19 times. They sold a total of 148,672 shares worth more than $10,389,459.87. The most recent insider tranaction occured on April, 15th when CAO Andrea Sabens sold 341 shares worth more than $20,882.84. Insiders at Lantheus own 1.5% of the company. Learn More about insider trades at Lantheus.
Information on this page was last updated on 4/15/2024.

Sam R. Leno Insider Trading History at Lantheus

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/8/2021	Sell	5,000	$21.17	$105,850.00	40,784
12/13/2019	Sell	11,508	$20.30	$233,612.40	38,072
6/7/2019	Sell	3,950	$25.33	$100,053.50	49,580

Sam R. Leno Buying and Selling Activity at Lantheus

Lantheus Company Overview

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Today's Range

Now: $65.20

$63.76

$65.27

50 Day Range

MA: $61.31

$56.52

$68.26

2 Week Range

Now: $65.20

$50.20

$100.85

Volume

602,997 shs

Average Volume

1,036,479 shs

Market Capitalization

$4.47 billion

P/E Ratio

14.05

Dividend Yield

N/A

Beta

0.53

Better than Bitcoin? The Biotech Stock with 46,751% Potential

From Behind the Markets | Ad

4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.

Get the name of the stock here >>>